Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution

J Virol. 2009 Jan;83(1):368-83. doi: 10.1128/JVI.01404-08. Epub 2008 Oct 15.

Abstract

The human immunodeficiency virus type 1 envelope glycoprotein (Env) complex is the principal focus of neutralizing antibody-based vaccines. The functional Env complex is a trimer consisting of six individual subunits: three gp120 molecules and three gp41 molecules. The individual subunits have proven unsuccessful as vaccines presumably because they do not resemble the functional Env complex. Variable domains and carbohydrates shield vulnerable neutralization epitopes on the functional Env complex. The deletion of variable loops has been shown to improve gp120's immunogenicity; however, problems have been encountered when introducing such modifications in stabilized Env trimer constructs. To address these issues, we have created a set of V1/V2 and V3 loop deletion variants in the context of complete virus to allow optimization by forced virus evolution. Compensatory second-site substitutions included the addition and/or removal of specific carbohydrates, changes in the disulfide-bonded architecture of the V1/V2 stem, the replacement of hydrophobic residues by hydrophilic and charged residues, and changes in distal parts of gp120 and gp41. These viruses displayed increased sensitivity to neutralizing antibodies, demonstrating the improved exposure of conserved domains. The results show that we can select for functionally improved Env variants with loop deletions through forced virus evolution. Selected evolved Env variants were transferred to stabilized Env trimer constructs and were shown to improve trimer expression and secretion. Based on these findings, we can make recommendations on how to delete the V1/V2 domain from recombinant Env trimers for vaccine and X-ray crystallography studies. In general, virus evolution may provide a powerful tool to optimize Env vaccine antigens.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Directed Molecular Evolution*
  • HIV Antibodies / immunology
  • HIV Antigens / genetics
  • HIV Antigens / immunology
  • HIV-1 / genetics*
  • HIV-1 / growth & development
  • HIV-1 / immunology
  • HIV-1 / isolation & purification*
  • Humans
  • Models, Molecular
  • Mutation*
  • Neutralization Tests
  • Protein Structure, Tertiary
  • Sequence Deletion
  • env Gene Products, Human Immunodeficiency Virus / genetics*
  • env Gene Products, Human Immunodeficiency Virus / immunology*

Substances

  • HIV Antibodies
  • HIV Antigens
  • env Gene Products, Human Immunodeficiency Virus